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Aims: Patients with multiple tumour localisations pose a particular problem to the pathologist when the
traditional combination of clinical data, morphology, and immunohistochemistry does not provide con-
clusive evidence to differentiate between metastasis or second primary, or does not identify the primary
location in cases of metastases and two primary tumours. Because this is crucial to decide on further
treatment, molecular techniques are increasingly being used as ancillary tools.
Methods: The value of comparative genomic hybridisation (CGH) to differentiate between metastasis
and second primary, or to identify the primary location in cases of metastases and two primary tumours
was studied in seven patients. CGH is a cytogenetic technique that allows the analysis of genome wide
amplifications, gains, and losses (deletions) in a tumour within a single experiment. The patterns of
these chromosomal aberrations at the different tumour localisations were compared.
Results: In all seven cases, CGH patterns of gains and losses supported the differentiation between
metastasis and second primary, or the identification of the primary location in cases of metastases and
two primary tumours.
Conclusion: The results illustrate the diagnostic value of CGH in patients with multiple tumours.
In day to day routine work, pathologists are faced with casesthat take more than a standard haematoxylin and eosinstain to solve the diagnostic problem and answer the
clinician’s questions. Patients with multiple tumour localisa-
tions belong to a special category in this respect. Of course, in
a large number of cases, in patients with a known and well
characterised primary tumour, the second tumour can be
confirmed—at least for all practical purposes—to be a metas-
tasis of this primary. In fact, this decision in general is not only
based on the histological comparison between the two tumour
samples, but also on the clinical plausibility. For example,
adenocarcinoma in the liver is regarded as a metastasis of the
patient’s colorectal cancer, the squamous cell cancer in a jugu-
lar lymph node as a metastasis of the patient’s laryngeal can-
cer, and adenocarcinoma in an axillary lymph node as a
metastasis of the patient’s breast cancer. In other cases, the
situation is less obvious, and the question of whether the
patient has a metastasis of his primary cancer, or whether a
second primary cancer has occurred, is difficult to answer,
even though this may be very important for clinical decision
making. In these cases, the question is: should the patient be
regarded as suffering from (high stage) metastatic disease, or
has a low stage second primary occurred, and should the
patient be treated accordingly with an intention to cure? The
pathologist plays a key role in this process of decision making
and is expected to produce the ultimate answer. However, it is
obvious that this is not always an easy task, and frequently
additional techniques are required. Immunohistochemistry is
often the initial method used, but is frequently not enough,
either because certain immunophenotypes are common to
several types of cancers, or because tumours are negative for
almost all markers. In addition, different samples from the
same tumour may show extreme phenotypical and immuno-
histochemical heterogeneity. Therefore, it seems logical to
focus not only on the phenotype, but also to look at the geno-
type. In our study, we present several cases in which compara-
tive genomic hybridisation (CGH) was applied in an attempt
to reach a diagnosis.
CGH is a technique that allows the detection of chromo-
somal copy number changes without the need for cell
culturing.1–3 It gives a global overview of chromosomal gains
and losses throughout the whole genome of a tumour. Thus,
CGH is a relatively fast screening technique that can point at
specific chromosomal regions that have been altered in the
genome. Because no cell culturing is required for CGH, this
technique has enabled tremendous progress in the analysis of
chromosomal changes in solid tumours. Applications of CGH
in cancer research include screening of tumours for genetic
aberrations4–16 (see also http://www.helsinki.fi/∼lgl_www/
CMG.html), searching for genes involved in the carcinogen-
esis of particular subsets of cancers,17 analysing tumours in
experimental models to provide more insight into tumour
progression,17 18 diagnostic classification,17 and prognosis
assessment.17–20 In addition to these oncological applications,
CGH analysis has also been used to study chromosomal aber-
rations in fetal and neonatal genomes.21 22
“Comparative genomic hybridisation gives a global
overview of chromosomal gains and losses throughout
the whole genome of a tumour”
CGH may prove to be useful for the differentiation between
a metastasis or second primary, and the identification of a pri-
mary location in cases of metastases and two (or more)
primary tumours. To investigate this possibility, we decided to
analyse several cases with CGH and to look for the
concordance of the chromosomal aberrations between multi-
ple tumour samples within one patient.
METHODS
DNA was isolated from paraffin wax embedded, formaldehyde
fixed tissue according the protocol described previously.3 CGH
was performed as described previously,3 and the results were
analysed with an Applied Imaging workstation (Applied
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Imaging, Newcastle upon Tyne, UK). In total, 18 tumours from
seven patients were analysed by CGH.
RESULTS
Figure 1 summarises the results.
Patient 1
A 66 year old woman presented with a polypoid tumour of the
gastric cardia. After resection, histopathological examination
showed a focus of poorly differentiated adenocarcinoma aris-
ing in a villous adenoma with superficial invasion of the sub-
mucosa. Surgical resection margins and a total of five regional
lymph nodes were free of tumour. After two years, on
endoscopical examination, a flat lesion was seen in the
squamous epithelium of the distal oesophagus within 5 cm of
the surgical anastomosis. Histopathology of the biopsy and the
subsequent mucosectomy specimen showed a superficially
invasive squamous cell carcinoma. Although the two tumour
samples showed a different histology, given the close
topographical relation between both lesions, the clinicians
were seeking for confirmation that the oesophageal tumour
was a second primary. Two samples of the gastric tumour (the
villous and the solid part) and one sample of the oesophageal
tumour were analysed by CGH. The squamous cell carcinoma
showed 15 chromosomal aberrations, whereas the two
samples of the gastric tumour showed only three and four
chromosomal aberrations, respectively. In addition, the
pattern of aberrations of the squamous carcinoma differed
from the two patterns seen in the adenocarcinoma. These
findings are in agreement with the observations that, in gen-
eral, squamous cell carcinomas show a more complex pattern
of chromosomal changes than adenocarcinomas.12 The CGH
Figure 1 Summary of the comparative genomic hybridisation results for all seven patients. SCC, squamous cell carcinoma.
Figure 2 Histology of the four tumours in patient 2. (A) Breast lesion (1987); (B) tumour in the omentum (1997); (C) ovarian tumour (1996);
(D) tumour in the duodenum (1999). All tumours showed solid fields of tumour cells with the occasional glandular lumen.
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results showed that the tumour in the gastric cardia and the
tumour in the distal oesophagus were genetically unrelated
and confirmed that the oesophageal tumour was a second
primary, so that there were no indications of metastasis of the
primary tumour.
Patient 2
A 51 year old woman presented with a medullary type of
breast cancer that was locally radically resected. There were no
lymph node metastases. Nine years later she presented with
an 11 cm poorly differentiated adenocarcinoma of the left
ovary and a 1.5 cm tumour with similar histology in the right
ovary; no abdominal metastases were present. Another year
later, she had a metastatic tumour removed from the
omentum, which proved to be a poorly differentiated
adenocarcinoma. Two years after that she underwent partial
duodenectomy because of an obstructing tumour mass, which
on microscopic examination also proved to be a poorly differ-
entiated adenocarcinoma. Clinically, the ovarian tumours
were thought to represent a second primary, although
histologically discrimination between the tumours (of the
breast, ovary, duodenum, and omentum) was not completely
straightforward (fig 2). BRST2 immunohistochemistry was
positive in the breast tumour and the metastases in the omen-
tum and duodenum. The two metastases had 13 CGH events
in common (fig 3), and therefore were thought to have devel-
oped from the same primary tumour. The breast carcinoma
from 1987 shared six events with the metastases, whereas
none of these six occurred in the ovarian tumour from 1996
(fig 4). It was concluded that the two metastases were derived
from the breast carcinoma and that the ovarian cancer was a
second primary.
Patient 3
A 76 year old woman underwent a lumpectomy for a 3 cm
large ductal adenocarcinoma in the right breast. The resection
margins were free but the sentinel node showed a metastasis.
Subsequent lymph node dissections of the right axilla yielded
nine lymph nodes free of tumour. Three years later the patient
presented with an undifferentiated carcinoma in the bladder.
On immunohistochemical evaluation, both tumours were
positive for cytokeratin, CAM5.2, AE1/3, and the progesterone
receptor. In addition, the breast cancer was positive for the
oestrogen receptor (bladder negative) and the bladder was
positive for cytokeratin 7 (CK7) and CK20 (breast negative).
Both tumours were negative for BRST2. CGH was performed
on both the breast and the bladder tumour. The breast tumour
showed many aberrations (n = 25), in contrast to the bladder
carcinoma, in which only nine chromosomal changes were
found. In addition, both tumours showed specific changes—
for example, the breast tumour showed amplification at
1q31–32, and in the bladder carcinoma amplifications were
present at both telomeres of chromosome 3 (a very rare
amplification). This virtually excluded the possibility that
both tumours shared a common origin.
Patient 4
At necropsy of a 91 year old woman, multiple tumour localisa-
tions were found in the supraclavicular lymph nodes,
pancreas, and right breast. The patient had a history of an
adenocarcinoma of the left breast for which she underwent a
Figure 3 Overview of comparative genomic hybridisation events in the four lesions described in patient 2. The bars on the right of each
ideogram represent gains, and the bars on the left losses.
Figure 4 Summary of the results from patient 2. The two
metastases have 13 comparative genomic hybridisation events in
common and are therefore considered to have developed from the
same primary tumour. The breast carcinoma from 1987 shared six
events with the metastases, whereas none of these six occurred in the
ovarian tumour from 1996. It was concluded that the two metastases
were derived from the breast carcinoma and that the ovarian cancer
was a second primary.
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mastectomy 40 years before she died. The tumour in the pan-
creas was histologically different from the other tumours (fig
5), but immunohistochemistry was inconclusive. All tumour
samples were positive for CAM5.2, CK7, AE1/3, and carci-
noembryonic antigen (CEA) and negative for BRST2.
CGH analyses of primary breast cancers and metachronous
metastases after several decades have been described.23 In this
patient, we performed CGH on the breast tumour, the pancre-
atic tumour, and one lymph node metastasis. Unfortunately,
there was no material available from the breast tumour
removed 40 years before death. The breast tumour showed 15
chromosomal aberrations, the pancreatic tumour showed nine
chromosomal aberrations, and the lymph node metastasis 21.
The breast and the pancreatic tumours had seven (of 15 and
nine, respectively) events in common. The breast cancer and
the lymph node metastasis shared nine (of 15 and 21, respec-
tively) events, and the pancreatic cancer and the lymph node
metastasis shared eight (of nine and 21, respectively) events.
These CGH results indicated that all the lesions had developed
from the same tumour. Based on the idea that the tumour
with the least changes is the primary, this would be the pan-
creatic tumour, although theoretically it is possible that all the
tumours found at necropsy had originated from the breast
cancer diagnosed 40 years before death. However, clinically,
such a long time interval before relapse is less likely.
Patient 5
A 59 year old woman presented with a tumour in the right
ovary with clear cell histology. Seven years before she had
undergone a nephrectomy because of a renal carcinoma of the
left side. Both the combination of a primary renal cell
carcinoma and an ovarian clear cell carcinoma, or the alterna-
tive, a renal cell carcinoma with a metastasis in the ovary, are
rare. Furthermore, the pattern of tumour spread (along the
para-aortal lymph nodes with no intra-abdominal metas-
tases) is remarkable for an ovarian adenocarcinoma. Some
differences were seen on histology and immunohistochemis-
try (the renal cell carcinoma was negative for CK7, CEA,
CA125, and vimentin, whereas the ovarian tumour was
positive for all these markers). CGH showed 11 chromosomal
aberrations in the renal cell carcinoma and 25 in the ovarian
tumour. Out of the total number of 30 different chromosomal
aberrations, the tumours had only five in common. In this
case, the combination of genotyping by CGH and immunophe-
notyping yielded sufficient information to classify the
tumours as two independent lesions, and it was therefore
concluded that the tumour in the ovary was a second primary.
Patient 6
A 72 year old man who underwent resection of the inferior
lobe of the right lung because of a 5.5 cm tumour was found
to have an additional 1.1 cm tumour in the same lobe that was
quite different histologically. The largest tumour had an
epithelial undifferentiated large cell phenotype, whereas the
smaller tumour showed a mesenchymal aspect, with polymor-
phic atypical spindle cells and many mitoses.
The total numbers of chromosomal aberrations detected by
CGH were 17 and 19, in the larger and smaller tumours,
respectively, of which they had 10 in common. Both lesions
showed several chromosomal aberrations that are rather typi-
cal for squamous cell carcinomas,12 such as gain of 3q and
11q13, and loss of 13q. Because similar levels of agreement
have been seen within tumours, the CGH results were consist-
ent with the two tumours being genetically related.24
Patient 7
A 58 year old woman presented with synchronous endome-
trioid carcinomas of the ovary and endometrium. Both
tumours were diploid as analysed with flow cytometry. CGH
was performed on both lesions and revealed only three events
in the uterus (8p−, 16q−, and Xp+) and two in the ovarian
carcinoma (12q−, 22q−). Because none of these chromosomal
aberrations was shared, it was concluded that these two
endometrioid tumours were not related, and thus they were
considered to be two primary tumours.
DISCUSSION
The traditional role of the pathologist has been the evaluation
of human tumour samples in a search for clues to their
histogenesis and anticipated clinical behaviour. Over the
years, this quest has benefited from the application of special-
ised techniques, which have become part of the pathologist’s
arsenal. In addition to light microscopic evaluation of haema-
toxylin eosin stained tissue sections, immunohistochemistry
has proved to be a particularly valuable adjunct in cancer
diagnosis. More recently, molecular pathological techniques
have been added to this repertoire of useful techniques.
Irrespective of the tools applied, every diagnosis in clinical
pathology, as one of the laboratory disciplines, should be con-
sidered as the result of a diagnostic test. For such a test to
make an optimal contribution to clinical decision making,
ideally it should be validated and implemented in a standard-
ised way.25 This includes defining the algorithm to calculate
the classifier, deciding on the optimal cut off point depending
on the clinical relevance, and ultimately extensive testing of
the performance of the test in terms of positive and negative
predictive value. This process is very demanding in terms of
labour and availability of clinically and pathologically well
documented series of specimens, and consequently it takes
many years. When the respective differential diagnoses
(which actually means the different diagnostic tests) in every
Figure 5 Histology of patient 4. (A) The breast lesion showed adenocarcinoma with predominant tubule formation and moderate cytonuclear
atypia, whereas (B) the pancreatic tumour and (C) lymph node metastases both showed poorly differentiated adenocarcinoma, with solid small
epithelial nests and moderate to strong nuclear atypia.
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day routine pathology are considered, in the present situation
only a subset is large and consistent enough to apply these
rules rigorously (for example, testing sentinel nodes for
tumour metastases, immunohistochemical panels for dis-
criminating between different types of adenocarcinomas).26 27
A major risk for following this strategy is that by the time the
process is completed, an alternative test emerges that is
implemented in diagnostic pathology without going through
this whole procedure. When we compare this with the
situation of putting a new drug on the market, this is a
remarkable situation, because the consequences of a sub-
standard test can be as equally severe as the consequences of
a substandard drug. If we want to develop clinical pathology
as an evidence based branch of medicine, it is obvious that we
should strive to extend our repertoire of validated tests.
Nevertheless, in many situations we have to provide
answers without having such a validated test available, and we
simply use the tools that are available. This can be acceptable
as long as both pathologists and clinicians are aware of the
limitations of the test used. In the case of obvious test results
(for example, the CGH results of two tumours are 100% iden-
tical or 100% different) we can provide an answer that has a
high degree of certainty, but in all other cases there is a poorly
defined level of uncertainty, which should be considered in the
ultimate diagnosis and communicated to the clinician who
has asked for the test. Against this background, we have
explored the possibilities of comparative genomic hybridisa-
tion for classifying multiple tumours within one patient as
related or independent lesions. It is clear that CGH at this
moment does not meet all the criteria described above for a
validated diagnostic test—for example, the cut off for deciding
whether or not tumours are related is not completely clear.
This is further hampered by the fact that tumours may share
identical chromosomal changes because they belong to the
same histological category. For example, in squamous cell car-
cinomas loss of 3p, gain of 3q, and amplifications at 11q13 are
relatively common, so that finding these changes in two
different squamous cell carcinomas provides little information
with respect to whether or not the tumours are related. In
addition, it can be difficult to draw conclusions when there are
relatively small numbers of chromosomal changes. It is more
convincing when two tumours share 10 of a total of 20 chro-
mosomal changes, rather than two of four different chromo-
somal changes. It is essential that we should look for
standardisation of test interpretation, preferably based on
clear data on the positive and negative predictive value of such
tests. However, as with many other tests in pathology, these
figures are not readily available, and we should be aware of
this fact when interpreting these tests and reporting our con-
clusions. Nevertheless, when taking these limitations into
account, the results of CGH could still contribute towards
clinical decision making, as illustrated in the cases presented
here.
“It is essential that we should look for standardisation of
test interpretation, preferably based on clear data on the
positive and negative predictive value of such tests”
When a second tumour presents in the same organ system
as the first, the question invariably arises as to whether it is a
recurrence or a second primary. The answer to this question
may have clinical implications, both with respect to further
diagnosis and treatment, and with respect to the patient, for
whom a difference can sometimes be made between the pres-
ence of metastatic disease versus repeated successful treat-
ment of primary malignancies. Morphological comparison
and an extended immunophenotypical profile of different
lesions can sometimes resolve the question, but the presence
of a clonal mutation or a characteristic pattern of genetic
alterations is the most direct way to establish a link between
the two lesions, or in contrast, to suggest that the
metachronous tumours represent independent events. For this
purpose, the pathologist has the choice between testing for the
presence of specific mutations (for example, the chance that
two independent tumours in one patient share the same p53
mutation is very low),28 using a panel of microsatellite
markers,29 or using CGH. Of these, CGH is the only one that
tests on a genome wide scale. In our present study,
chromosome based CGH has been applied. A new develop-
ment in this respect is microarray based CGH, one of the “DNA
chip” technologies. With this approach, chromosomes are no
longer used as a template for hybridisation, but an array of
microscopically small spots of genomic DNA is used instead.
Every spot represents a unique DNA sequence for which the
chromosomal locus is known.30 31 Microarray CGH has a higher
resolution and sensitivity, and data analysis is more straight-
forward than with chromosome based CGH. It is to be
expected that this technique will become widely used in rou-
tine pathology testing some time in the future.
. . . . . . . . . . . . . . . . . . . . .
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